Fragile X Syndrome - 2018 Pipeline Insight Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Fragile X Syndrome - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Fragile X Syndrome development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type

Scope

• The report provides a snapshot of the pipeline development for Fragile X Syndrome
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Fragile X Syndrome
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Fragile X Syndrome
• The report also covers the dormant and discontinued pipeline projects related to Fragile X Syndrome

Companies Featured

• Aelis Farma SAS
• AMO Pharma Ltd.
• Anavex Life Sciences Corp.
• Confluence Pharmaceuticals LLC
• DRI Biosciences Corp.
• Eli Lilly and Company
• Fulcrum Therapeutics Inc.
• GlaxoSmithKline PLC
• GW Pharmaceuticals PLC
• Marinus Pharmaceuticals Inc.
• Neuren Pharmaceuticals Ltd.
• Neuron Biopharma SA
• Ovid Therapeutics Inc.

Key Topics Covered

1. Report Introduction

2. Fragile X Syndrome Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Fragile X Syndrome

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment

• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rn5pdb/fragile_x?w=4